Acute myocardial infarction (MI) results from coronary flow disturbance with thrombus
deposition, in addition to accumulation of the atherosclerotic plaque in the coronary artery …

IL-1 (interleukin-1) contributes to the inflammatory response during ST-segment–elevation
myocardial infarction (STEMI). 1 Goflikicept (RPH-104) is a novel IL-1 inhibitor, acting as an …

Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-
elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we …

Background Little is known about the role of interleukin (IL) in patients with acute myocardial
infarction (MI), especially soluble IL-2 receptor (sIL-2R) and IL-8. We aim to evaluate, in MI …

Acute myocardial infarction (AMI) and heart failure (HF) are characterized by an intense
inflammatory response that contributes to progression of the injury and dysfunction (1) …

Abstract Background The IABP-SHOCK-trial was a morbidity-based randomized controlled
trial in patients with infarction-related cardiogenic shock (CS), which used the change of the …

In the infarcted heart, the damage‐associated molecular pattern proteins released by
necrotic cells trigger both myocardial and systemic inflammatory responses. Induction of …

Inflammation is a cornerstone of the post-myocardial infarction healing process. However,
an exuberant systemic as well as loco-regional inflammatory response may have a direct …

Background Atherosclerosis is a chronic inflammatory disease of the artery wall. Regulatory
T cells (Tregs) limit inflammation and promote tissue healing. Low doses of interleukin (IL)-2 …

Background Inflammatory responses post STEMI may mediate major adverse
cardiovascular events (MACE). This is the first systematic review to map leukocyte response …